A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

计划入组 116 人 · 首次发布于 2023 年 11 月 20 日

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

计划入组 220 人 · 首次发布于 2024 年 3 月 5 日

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

计划入组 149 人 · 首次发布于 2023 年 4 月 25 日

Linvoseltamab(Lynozyfic)

GCPK

GCP Laboratories, Inc.

United States

GCP-Service International West GmbH

Germany

GCP Service International Ltd & Co KG

Germany

Regeneron's Lynozyfic Receives FDA Approval for Multiple Myeloma with 70% Response Rate

FDA Issues Complete Response Letter for Regeneron's Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Regeneron's Linvoseltamab Shows Promising Results in Phase 1b Trial for Multiple Myeloma